𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): the final report

✍ Scribed by Toshihiko Wakabayashi; Takamasa Kayama; Ryo Nishikawa; Hiroshi Takahashi; Naoya Hashimoto; Jun Takahashi; Tomokazu Aoki; Kazuhiko Sugiyama; Masatoshi Ogura; Atsushi Natsume; Jun Yoshida

Publisher
Springer US
Year
2011
Tongue
English
Weight
183 KB
Volume
104
Category
Article
ISSN
0167-594X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Benefits of interferon-β and temozolomid
Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter : A multicenter study
✍ Kazuya Motomura; Atsushi Natsume; Yugo Kishida; Hiroyuki Higashi; Yutaka Kondo; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 409 KB

## Abstract ## BACKGROUND: The aim of the current study was to catalog genomic and epigenomic abnormalities in newly diagnosed glioblastoma patients and determine the correlation among clinical, genetic, and epigenetic profiles and clinical outcome. ## METHODS: This study retrospectively include

Final report of a phase I/II trial of hy
Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas: Radiation therapy oncology group study 83-02
✍ Maria Werner-Wasik; Charles B. Scott; Diana F. Nelson; Laurie E. Gaspar; Kevin J 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 825 KB

## BACKGROUND. Efforts to improve local control and survival by increasing the dose of once-daily radiation therapy beyond 70 Gray (Gy) for patients with malignant gliomas have as yet been unsuccessful. Hyperfractionated radiation therapy (HF) should allow for delivery of a higher total dose witho